Pulmonary carcinoids (PCs) display the common features of all well-differentiated neuroendocrine neoplasms (NEN) and are classified as low- and intermediate-grade malignant tumours (i.e., typical and atypical carcinoid, respectively). There is a paucity of randomised studies dedicated to advanced PCs and management principles are drawn from the larger gastroenteropancreatic NEN experience. There is growing evidence that NEN anatomic subgroups have different biology and different responses to treatment and, therefore, should be investigated as separate entities in clinical trials. In this review, we discuss the existing evidence and limitations of tumour classification, diagnostics and staging, prognostication, and treatment in the setting of PC, with focus on unmet medical needs and directions for the future.

1.
Yao
JC
,
Hassan
M
,
Phan
A
,
Dagohoy
C
,
Leary
C
,
Mares
JE
, et al.
One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
.
J Clin Oncol
.
2008
Jun
;
26
(
18
):
3063
72
.
[PubMed]
0732-183X
2.
Korse
CM
,
Taal
BG
,
van Velthuysen
ML
,
Visser
O
.
Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry
.
Eur J Cancer
.
2013
May
;
49
(
8
):
1975
83
.
[PubMed]
0959-8049
3.
Naalsund
A
,
Rostad
H
,
Strøm
EH
,
Lund
MB
,
Strand
TE
.
Carcinoid lung tumors—incidence, treatment and outcomes: a population-based study
.
Eur J Cardiothorac Surg
.
2011
Apr
;
39
(
4
):
565
9
.
[PubMed]
1010-7940
4.
Rekhtman
N
.
Neuroendocrine tumors of the lung: an update
.
Arch Pathol Lab Med
.
2010
Nov
;
134
(
11
):
1628
38
.
[PubMed]
1543-2165
5.
Ferolla
P
,
Brizzi
MP
,
Meyer
T
,
Mansoor
W
,
Mazieres
J
,
Do Cao
C
, et al.
Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial
.
Lancet Oncol
.
2017
Dec
;
18
(
12
):
1652
64
.
[PubMed]
1470-2045
6.
Travis
WD
,
Brambilla
E
,
Burke
A
,
Marx
A
,
Nicholson
AG
.
WHO classification of tumours of the lung, pleura, thymus and heart
.
Lyon
:
International Agency for Research on Cancer
;
2015
.
7.
Amin
MB
,
Edge
SB
,
Greene
F
,
Byrd
D
,
Brookland
RW
.
MK, Gershenwald JC, CC, et al. AJCC cancer staging manual
. 8th ed.
New York
:
Springer
;
2017
.
8.
Caplin
ME
,
Baudin
E
,
Ferolla
P
,
Filosso
P
,
Garcia-Yuste
M
,
Lim
E
, et al.;
ENETS consensus conference participants
.
Pulmonary neuroendocrine (carcinoid) tumors: european Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids
.
Ann Oncol
.
2015
Aug
;
26
(
8
):
1604
20
.
[PubMed]
0923-7534
9.
Phan
AT
,
Öberg
K
,
Choi
J
,
Harrison
LH
 Jr
,
Hassan
MM
,
Strosberg
JR
, et al.;
North American Neuroendocrine Tumor Society (NANETS)
.
NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus)
.
Pancreas
.
2010
Aug
;
39
(
6
):
784
98
.
[PubMed]
0885-3177
10.
Gustafsson
BI
,
Kidd
M
,
Chan
A
,
Malfertheiner
MV
,
Modlin
IM
.
Bronchopulmonary neuroendocrine tumors
.
Cancer
.
2008
Jul
;
113
(
1
):
5
21
.
[PubMed]
0008-543X
11.
Greaves
M
,
Burova
E
.
Flushing: causes, investigation and clinical consequences
.
J Eur Acad Dermatol Venereol
.
1997
;
8
(
2
):
91
100
. 0926-9959
12.
Wirtschafter
E
,
Walts
AE
,
Liu
ST
,
Marchevsky
AM
.
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia of the lung (DIPNECH): current best evidence
.
Hai
.
2015
Oct
;
193
(
5
):
659
67
.
[PubMed]
0436-5712
13.
Benson
RE
,
Rosado-de-Christenson
ML
,
Martínez-Jiménez
S
,
Kunin
JR
,
Pettavel
PP
.
Spectrum of pulmonary neuroendocrine proliferations and neoplasms
.
Radiographics
.
2013
Oct
;
33
(
6
):
1631
49
.
[PubMed]
0271-5333
14.
Gosney
JR
.
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia as a precursor to pulmonary neuroendocrine tumors.
CHEST Journal.
2004
;125(5_suppl):108S-S.
15.
Miller
MA
,
Mark
GJ
,
Kanarek
D
.
Multiple peripheral pulmonary carcinoids and tumorlets of carcinoid type, with restrictive and obstructive lung disease
.
Am J Med
.
1978
Aug
;
65
(
2
):
373
8
.
[PubMed]
0002-9343
16.
Aguayo
SM
,
Miller
YE
,
Waldron
JA
 Jr
,
Bogin
RM
,
Sunday
ME
,
Staton
GW
 Jr
, et al.
Brief report: idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease
.
N Engl J Med
.
1992
Oct
;
327
(
18
):
1285
8
.
[PubMed]
0028-4793
17.
Van Sickle
DG
.
Carcinoid tumors. Analysis of 61 cases, including 11 cases of carcinoid syndrome
.
Cleve Clin Q
.
1972
;
39
(
2
):
79
86
.
[PubMed]
0009-8787
18.
Klimstra
DS
,
Modlin
IR
,
Coppola
D
,
Lloyd
RV
,
Suster
S
.
The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems
.
Pancreas
.
2010
Aug
;
39
(
6
):
707
12
.
[PubMed]
0885-3177
19.
Tang
LH
,
Gonen
M
,
Hedvat
C
,
Modlin
IM
,
Klimstra
DS
.
Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods
.
Am J Surg Pathol
.
2012
Dec
;
36
(
12
):
1761
70
.
[PubMed]
0147-5185
20.
Sobin
LH
,
Gospodarowicz
MK
,
Wittekind
C
.
TNM classification of malignant tumours
.
John Wiley & Sons
;
2011
.
21.
Rindi
G
,
Klöppel
G
,
Alhman
H
,
Caplin
M
,
Couvelard
A
,
de Herder
WW
, et al.;
all other Frascati Consensus Conference participants
;
European Neuroendocrine Tumor Society (ENETS)
.
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system
.
Virchows Arch
.
2006
Oct
;
449
(
4
):
395
401
.
[PubMed]
0945-6317
22.
Pelosi
G
,
Rindi
G
,
Travis
WD
,
Papotti
M
.
Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice
.
J Thorac Oncol
.
2014
Mar
;
9
(
3
):
273
84
.
[PubMed]
1556-0864
23.
Walts
AE
,
Ines
D
,
Marchevsky
AM
.
Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors
.
Mod Pathol
.
2012
Sep
;
25
(
9
):
1258
64
.
[PubMed]
0893-3952
24.
Costes
V
,
Marty-Ané
C
,
Picot
MC
,
Serre
I
,
Pujol
JL
,
Mary
H
, et al.
Typical and atypical bronchopulmonary carcinoid tumors: a clinicopathologic and KI-67-labeling study
.
Hum Pathol
.
1995
Jul
;
26
(
7
):
740
5
.
[PubMed]
0046-8177
25.
Grimaldi
F
,
Muser
D
,
Beltrami
CA
,
Machin
P
,
Morelli
A
,
Pizzolitto
S
, et al.
Partitioning of bronchopulmonary carcinoids in two different prognostic categories by ki-67 score
.
Front Endocrinol (Lausanne)
.
2011
Aug
;
2
:
20
.
[PubMed]
1664-2392
26.
Rugge
M
,
Fassan
M
,
Clemente
R
,
Rizzardi
G
,
Giacomelli
L
,
Pennelli
G
, et al.
Bronchopulmonary carcinoid: phenotype and long-term outcome in a single-institution series of Italian patients
.
Clin Cancer Res
.
2008
Jan
;
14
(
1
):
149
54
.
[PubMed]
1078-0432
27.
Zahel
T
,
Krysa
S
,
Herpel
E
,
Stenzinger
A
,
Goeppert
B
,
Schirmacher
P
, et al.
Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach
.
Virchows Arch
.
2012
Mar
;
460
(
3
):
299
308
.
[PubMed]
0945-6317
28.
Granberg
D
,
Wilander
E
,
Öberg
K
,
Skogseid
B
.
Prognostic markers in patients with typical bronchial carcinoid tumors
.
J Clin Endocrinol Metab
.
2000
Sep
;
85
(
9
):
3425
30
.
[PubMed]
0021-972X
29.
Marchiò
C
,
Gatti
G
,
Massa
F
,
Bertero
L
,
Filosso
P
,
Pelosi
G
, et al.
Distinctive pathological and clinical features of lung carcinoids with high proliferation index
.
Virchows Arch
.
2017
Dec
;
471
(
6
):
713
20
.
[PubMed]
0945-6317
30.
Quinn
AM
,
Chaturvedi
A
,
Nonaka
D
.
High-grade Neuroendocrine Carcinoma of the Lung With Carcinoid Morphology: A Study of 12 Cases
.
Am J Surg Pathol
.
2017
Feb
;
41
(
2
):
263
70
.
[PubMed]
0147-5185
31.
Travis
WD
,
Giroux
DJ
,
Chansky
K
,
Crowley
J
,
Asamura
H
,
Brambilla
E
, et al.;
International Staging Committee and Participating Institutions
.
The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer
.
J Thorac Oncol
.
2008
Nov
;
3
(
11
):
1213
23
.
[PubMed]
1556-0864
32.
Filosso
P
,
Guerrera
F
,
Evangelista
A
,
Welter
S
,
Thomas
P
,
Casado
P
, et al.
Prognostic model of survival for typical bronchial carcinoid tumours: analysis of 1109 patients on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours Working Group. European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery.
2015
;48(3):441-7; discussion 7.
33.
Patchell
RA
,
Posner
JB
.
Neurologic complications of carcinoid
.
Neurology
.
1986
Jun
;
36
(
6
):
745
9
.
[PubMed]
0028-3878
34.
Hlatky
R
,
Suki
D
,
Sawaya
R
.
Carcinoid metastasis to the brain
.
Cancer
.
2004
Dec
;
101
(
11
):
2605
13
.
[PubMed]
0008-543X
35.
Sundin
A
,
Arnold
R
,
Baudin
E
,
Cwikla
JB
,
Eriksson
B
,
Fanti
S
, et al.;
Antibes Consensus Conference participants
.
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging
.
Neuroendocrinology
.
2017
;
105
(
3
):
212
44
.
[PubMed]
0028-3835
36.
Lamarca
A
,
Pritchard
DM
,
Westwood
T
,
Papaxoinis
G
,
Nonaka
D
,
Vinjamuri
S
, et al.
68Gallium DOTANOC-PET Imaging in Lung Carcinoids: Impact on Patients’ Management
.
Neuroendocrinology
.
2017
.
[PubMed]
0028-3835
37.
Filosso
PL
,
Guerrera
F
,
Thomas
P
,
Brunelli
A
,
Lim
E
,
Garcia-Yuste
M
, et al.;
European Society of Thoracic Surgeons Neuroendocrine Tumors of the Lung Working Group
.
Management of bronchial carcinoids: international practice survey among the European Society of Thoracic Surgeons
.
Future Oncol
.
2016
Sep
;
12
(
17
):
1985
99
.
[PubMed]
1479-6694
38.
Pattenden
HA
,
Leung
M
,
Beddow
E
,
Dusmet
M
,
Nicholson
AG
,
Shackcloth
M
, et al.
Test performance of PET-CT for mediastinal lymph node staging of pulmonary carcinoid tumours.
Thorax.
2014
:thoraxjnl-2014-205899.
39.
Hemminki
K
,
Li
X
.
Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden
.
Int J Cancer
.
2001
Nov
;
94
(
3
):
444
8
.
[PubMed]
0020-7136
40.
Sachithanandan
N
,
Harle
RA
,
Burgess
JR
.
Bronchopulmonary carcinoid in multiple endocrine neoplasia type 1
.
Cancer
.
2005
Feb
;
103
(
3
):
509
15
.
[PubMed]
0008-543X
41.
Leotlela
PD
,
Jauch
A
,
Holtgreve-Grez
H
,
Thakker
RV
.
Genetics of neuroendocrine and carcinoid tumours
.
Endocr Relat Cancer
.
2003
Dec
;
10
(
4
):
437
50
.
[PubMed]
1351-0088
42.
Ferolla
P
,
Daddi
N
,
Urbani
M
,
Semeraro
A
,
Ribacchi
R
,
Giovenali
P
, et al.;
Regional Multidisciplinary Group for the Diagnosis and Treatment of Neuroendocrine Tumors, CRO, Umbria Region Cancer Network, Italy
.
Tumorlets, multicentric carcinoids, lymph-nodal metastases, and long-term behavior in bronchial carcinoids
.
J Thorac Oncol
.
2009
Mar
;
4
(
3
):
383
7
.
[PubMed]
1556-0864
43.
Thakker
RV
,
Newey
PJ
,
Walls
GV
,
Bilezikian
J
,
Dralle
H
,
Ebeling
PR
, et al.;
Endocrine Society
.
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)
.
J Clin Endocrinol Metab
.
2012
Sep
;
97
(
9
):
2990
3011
.
[PubMed]
0021-972X
44.
Isidori
AM
,
Lenzi
A
.
Ectopic ACTH syndrome
.
Arq Bras Endocrinol Metabol
.
2007
Nov
;
51
(
8
):
1217
25
.
[PubMed]
0004-2730
45.
Isidori
AM
,
Kaltsas
GA
,
Pozza
C
,
Frajese
V
,
Newell-Price
J
,
Reznek
RH
, et al.
The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up
.
J Clin Endocrinol Metab
.
2006
Feb
;
91
(
2
):
371
7
.
[PubMed]
0021-972X
46.
Ilias
I
,
Torpy
DJ
,
Pacak
K
,
Mullen
N
,
Wesley
RA
,
Nieman
LK
.
Cushing’s syndrome due to ectopic corticotropin secretion: twenty years’ experience at the National Institutes of Health
.
J Clin Endocrinol Metab
.
2005
Aug
;
90
(
8
):
4955
62
.
[PubMed]
0021-972X
47.
Shrager
JB
,
Wright
CD
,
Wain
JC
,
Torchiana
DF
,
Grillo
HC
,
Mathisen
DJ
.
Bronchopulmonary carcinoid tumors associated with Cushing’s syndrome: a more aggressive variant of typical carcinoid
.
J Thorac Cardiovasc Surg
.
1997
Sep
;
114
(
3
):
367
75
.
[PubMed]
0022-5223
48.
Pass
HI
,
Doppman
JL
,
Nieman
L
,
Stovroff
M
,
Vetto
J
,
Norton
JA
, et al.
Management of the ectopic ACTH syndrome due to thoracic carcinoids
.
Ann Thorac Surg
.
1990
Jul
;
50
(
1
):
52
7
.
[PubMed]
0003-4975
49.
Davi’
MV
,
Cosaro
E
,
Piacentini
S
,
Reimondo
G
,
Albiger
N
,
Arnaldi
G
, et al.
Prognostic factors in ectopic Cushing’s syndrome due to neuroendocrine tumors: a multicenter study
.
Eur J Endocrinol
.
2017
Apr
;
176
(
4
):
451
9
.
[PubMed]
0804-4643
50.
Kamp
K
,
Alwani
RA
,
Korpershoek
E
,
Franssen
GJ
,
de Herder
WW
,
Feelders
RA
.
Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors
.
Eur J Endocrinol
.
2016
Mar
;
174
(
3
):
271
80
.
[PubMed]
0804-4643
51.
Forde
PM
,
Hooker
CM
,
Boikos
SA
,
Petrini
I
,
Giaccone
G
,
Rudin
CM
, et al.
Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report
.
J Thorac Oncol
.
2014
Mar
;
9
(
3
):
414
8
.
[PubMed]
1556-0864
52.
Gut
P
,
Czarnywojtek
A
,
Fischbach
J
,
Bączyk
M
,
Ziemnicka
K
,
Wrotkowska
E
, et al.
Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls
.
Arch Med Sci
.
2016
Feb
;
12
(
1
):
1
9
.
[PubMed]
1734-1922
53.
Zatelli
MC
,
Torta
M
,
Leon
A
,
Ambrosio
MR
,
Gion
M
,
Tomassetti
P
, et al.;
Italian CromaNet Working Group
.
Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study
.
Endocr Relat Cancer
.
2007
Jun
;
14
(
2
):
473
82
.
[PubMed]
1351-0088
54.
Modlin
IM
,
Gustafsson
BI
,
Moss
SF
,
Pavel
M
,
Tsolakis
AV
,
Kidd
M
.
Chromogranin A—biological function and clinical utility in neuro endocrine tumor disease
.
Ann Surg Oncol
.
2010
Sep
;
17
(
9
):
2427
43
.
[PubMed]
1068-9265
55.
Filosso
PL
,
Kidd
M
,
Roffinella
M
,
Lewczuk
A
,
Chung
KM
,
Kolasinska-Cwikla
A
, et al.
The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progression
.
Eur J Cardiothorac Surg
.
2017
.
[PubMed]
1010-7940
56.
Fernandez-Cuesta
L
,
Peifer
M
,
Lu
X
,
Sun
R
,
Ozretić
L
,
Seidal
D
, et al.
Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids
.
Nat Commun
.
2014
Mar
;
5
(
1
):
3518
.
[PubMed]
2041-1723
57.
Umemura
S
,
Mimaki
S
,
Makinoshima
H
,
Tada
S
,
Ishii
G
,
Ohmatsu
H
, et al.
Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis
.
J Thorac Oncol
.
2014
Sep
;
9
(
9
):
1324
31
.
[PubMed]
1556-0864
58.
Govindan
R
,
Ding
L
,
Griffith
M
,
Subramanian
J
,
Dees
ND
,
Kanchi
KL
, et al.
Genomic landscape of non-small cell lung cancer in smokers and never-smokers
.
Cell
.
2012
Sep
;
150
(
6
):
1121
34
.
[PubMed]
0092-8674
59.
George
J
,
Lim
JS
,
Jang
SJ
,
Cun
Y
,
Ozretić
L
,
Kong
G
, et al.
Comprehensive genomic profiles of small cell lung cancer
.
Nature
.
2015
Aug
;
524
(
7563
):
47
53
.
[PubMed]
0028-0836
60.
Vollbrecht
C
,
Werner
R
,
Walter
RF
,
Christoph
DC
,
Heukamp
LC
,
Peifer
M
, et al.
Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group
.
Br J Cancer
.
2015
Dec
;
113
(
12
):
1704
11
.
[PubMed]
0007-0920
61.
Simbolo
M
,
Mafficini
A
,
Sikora
KO
,
Fassan
M
,
Barbi
S
,
Corbo
V
, et al.
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D
.
J Pathol
.
2017
Mar
;
241
(
4
):
488
500
.
[PubMed]
0022-3417
62.
Filosso
PL
,
Rena
O
,
Guerrera
F
,
Moreno Casado
P
,
Sagan
D
,
Raveglia
F
, et al.;
ESTS NETs-WG Steering Committee
.
Clinical management of atypical carcinoid and large-cell neuroendocrine carcinoma: a multicentre study on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours of the Lung Working Group
.
Eur J Cardiothorac Surg
.
2015
Jul
;
48
(
1
):
55
64
.
[PubMed]
1010-7940
63.
Daddi
N
,
Ferolla
P
,
Urbani
M
,
Semeraro
A
,
Avenia
N
,
Ribacchi
R
, et al.
Surgical treatment of neuroendocrine tumors of the lung
.
Eur J Cardiothorac Surg
.
2004
Oct
;
26
(
4
):
813
7
.
[PubMed]
1010-7940
64.
Lim
E
,
Yap
YK
,
De Stavola
BL
,
Nicholson
AG
,
Goldstraw
P
.
The impact of stage and cell type on the prognosis of pulmonary neuroendocrine tumors
.
J Thorac Cardiovasc Surg
.
2005
Oct
;
130
(
4
):
969
72
.
[PubMed]
0022-5223
65.
Stamatis
G
,
Freitag
L
,
Greschuchna
D
.
Limited and radical resection for tracheal and bronchopulmonary carcinoid tumour.
Report on 227 cases. European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery.
1989
;4(10):527-32; discussion 33.
66.
Pavel
M
,
O’Toole
D
,
Costa
F
,
Capdevila
J
,
Gross
D
,
Kianmanesh
R
, et al.;
Vienna Consensus Conference participants
.
ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site
.
Neuroendocrinology
.
2016
;
103
(
2
):
172
85
.
[PubMed]
0028-3835
67.
Franko
J
,
Feng
W
,
Yip
L
,
Genovese
E
,
Moser
AJ
.
Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients
.
J Gastrointest Surg
.
2010
Mar
;
14
(
3
):
541
8
.
[PubMed]
1091-255X
68.
Yuan
CH
,
Wang
J
,
Xiu
DR
,
Tao
M
,
Ma
ZL
,
Jiang
B
, et al.
Meta-analysis of liver resection versus nonsurgical treatments for pancreatic neuroendocrine tumors with liver metastases
.
Ann Surg Oncol
.
2016
Jan
;
23
(
1
):
244
9
.
[PubMed]
1068-9265
69.
Watzka
FM
,
Fottner
C
,
Miederer
M
,
Schad
A
,
Weber
MM
,
Otto
G
, et al.
Surgical therapy of neuroendocrine neoplasm with hepatic metastasis: patient selection and prognosis
.
Langenbecks Arch Surg
.
2015
Apr
;
400
(
3
):
349
58
.
[PubMed]
1435-2443
70.
Mayo
SC
,
Herman
JM
,
Cosgrove
D
,
Bhagat
N
,
Kamel
I
,
Geschwind
JF
, et al.
Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies
.
J Am Coll Surg
.
2013
Jan
;
216
(
1
):
123
34
.
[PubMed]
1072-7515
71.
Sarmiento
JM
,
Heywood
G
,
Rubin
J
,
Ilstrup
DM
,
Nagorney
DM
,
Que
FG
.
Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival
.
J Am Coll Surg
.
2003
Jul
;
197
(
1
):
29
37
.
[PubMed]
1072-7515
72.
Pavel
ME
,
Hainsworth
JD
,
Baudin
E
,
Peeters
M
,
Hörsch
D
,
Winkler
RE
, et al.;
RADIANT-2 Study Group
.
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
.
Lancet
.
2011
Dec
;
378
(
9808
):
2005
12
.
[PubMed]
0140-6736
73.
Yao
JC
,
Fazio
N
,
Singh
S
,
Buzzoni
R
,
Carnaghi
C
,
Wolin
E
, et al.;
RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group
.
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
.
Lancet
.
2016
Mar
;
387
(
10022
):
968
77
.
[PubMed]
0140-6736
74.
Wirth
LJ
,
Carter
MR
,
Jänne
PA
,
Johnson
BE
.
Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy
.
Lung Cancer
.
2004
May
;
44
(
2
):
213
20
.
[PubMed]
0169-5002
75.
Granberg
D
,
Eriksson
B
,
Wilander
E
,
Grimfjärd
P
,
Fjällskog
ML
,
Öberg
K
, et al.
Experience in treatment of metastatic pulmonary carcinoid tumors
.
Ann Oncol
.
2001
Oct
;
12
(
10
):
1383
91
.
[PubMed]
0923-7534
76.
Moertel
CG
,
Hanley
JA
.
Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome
.
Cancer Clin Trials
.
1979
;
2
(
4
):
327
34
.
[PubMed]
0190-1206
77.
Sun
W
,
Lipsitz
S
,
Catalano
P
,
Mailliard
JA
,
Haller
DG
;
Eastern Cooperative Oncology Group
.
Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281
.
J Clin Oncol
.
2005
Aug
;
23
(
22
):
4897
904
.
[PubMed]
0732-183X
78.
Turner
NC
,
Strauss
SJ
,
Sarker
D
,
Gillmore
R
,
Kirkwood
A
,
Hackshaw
A
, et al.
Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours
.
Br J Cancer
.
2010
Mar
;
102
(
7
):
1106
12
.
[PubMed]
0007-0920
79.
Crona
J
,
Fanola
I
,
Lindholm
DP
,
Antonodimitrakis
P
,
Öberg
K
,
Eriksson
B
, et al.
Effect of temozolomide in patients with metastatic bronchial carcinoids
.
Neuroendocrinology
.
2013
;
98
(
2
):
151
5
.
[PubMed]
0028-3835
80.
Ekeblad
S
,
Sundin
A
,
Janson
ET
,
Welin
S
,
Granberg
D
,
Kindmark
H
, et al.
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors
.
Clin Cancer Res
.
2007
May
;
13
(
10
):
2986
91
.
[PubMed]
1078-0432
81.
Spada
F
,
Fumagalli
C
,
Antonuzzo
L
,
Messerini
L
,
Radice
D
,
Di Rocco
R
, et al.
Capecitabine plus temozolomide (CAP-TEM) in patients with advanced neuroendocrine neoplasms (NEN): An Italian multicenter retrospective analysis
.
American Society of Clinical Oncology
;
2014
.
82.
Hegi
ME
,
Diserens
AC
,
Gorlia
T
,
Hamou
MF
,
de Tribolet
N
,
Weller
M
, et al.
MGMT gene silencing and benefit from temozolomide in glioblastoma
.
N Engl J Med
.
2005
Mar
;
352
(
10
):
997
1003
.
[PubMed]
0028-4793
83.
Kulke
MH
,
Hornick
JL
,
Frauenhoffer
C
,
Hooshmand
S
,
Ryan
DP
,
Enzinger
PC
, et al.
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors
.
Clin Cancer Res
.
2009
Jan
;
15
(
1
):
338
45
.
[PubMed]
1078-0432
84.
Reubi
JC
,
Waser
B
,
Schaer
JC
,
Laissue
JA
.
Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands
.
Eur J Nucl Med
.
2001
Jul
;
28
(
7
):
836
46
.
[PubMed]
0340-6997
85.
Reubi
J.
Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy.
The quarterly journal of nuclear medicine: official publication of the Italian Association of Nuclear Medicine (AIMN)[and] the International Association of Radiopharmacology (IAR).
1997
;41(2):63-70.
86.
Binderup
T
,
Knigge
U
,
Mellon Mogensen
A
,
Palnaes Hansen
C
,
Kjaer
A
.
Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors
.
Neuroendocrinology
.
2008
;
87
(
4
):
223
32
.
[PubMed]
0028-3835
87.
Kaemmerer
D
,
Specht
E
,
Sänger
J
,
Wirtz
RM
,
Sayeg
M
,
Schulz
S
, et al.
Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markers
.
J Clin Endocrinol Metab
.
2015
Mar
;
100
(
3
):
831
40
.
[PubMed]
0021-972X
88.
Lo Russo
G
,
Pusceddu
S
,
Prinzi
N
,
Imbimbo
M
,
Proto
C
,
Signorelli
D
, et al.
Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors
.
Tumour Biol
.
2016
Oct
;
37
(
10
):
12991
3003
.
[PubMed]
1010-4283
89.
Ianniello
A
,
Sansovini
M
,
Severi
S
,
Nicolini
S
,
Grana
CM
,
Massri
K
, et al.
Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET
.
Eur J Nucl Med Mol Imaging
.
2016
Jun
;
43
(
6
):
1040
6
.
[PubMed]
1619-7070
90.
van Vliet
EI
,
Krenning
EP
,
Teunissen
JJ
,
Bergsma
H
,
Kam
BL
,
Kwekkeboom
DJ
.
Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0,Tyr3]octreotate
.
J Nucl Med
.
2013
Oct
;
54
(
10
):
1689
96
.
[PubMed]
0161-5505
91.
Mariniello
A
,
Bodei
L
,
Tinelli
C
,
Baio
SM
,
Gilardi
L
,
Colandrea
M
, et al.
Long-term results of PRRT in advanced bronchopulmonary carcinoid
.
Eur J Nucl Med Mol Imaging
.
2016
Mar
;
43
(
3
):
441
52
.
[PubMed]
1619-7070
92.
Imhof
A
,
Brunner
P
,
Marincek
N
,
Briel
M
,
Schindler
C
,
Rasch
H
, et al.
Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers
.
J Clin Oncol
.
2011
Jun
;
29
(
17
):
2416
23
.
[PubMed]
0732-183X
93.
Brabander
T
,
Van der Zwan
WA
,
Teunissen
JJ
,
Kam
BL
,
Feelders
RA
,
de Herder
WW
, et al.
Long-term efficacy, survival and safety of [177Lu-DOTA0, Tyr3] octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clinical Cancer Research.
2017
:clincanres. 2743.016.
94.
Granberg
D
,
Wilander
E
,
Öberg
K
.
Expression of tyrosine kinase receptors in lung carcinoids
.
Tumour Biol
.
2006
;
27
(
3
):
153
7
.
[PubMed]
1010-4283
95.
Kulke
MH
,
Lenz
HJ
,
Meropol
NJ
,
Posey
J
,
Ryan
DP
,
Picus
J
, et al.
Activity of sunitinib in patients with advanced neuroendocrine tumors
.
J Clin Oncol
.
2008
Jul
;
26
(
20
):
3403
10
.
[PubMed]
0732-183X
96.
Grande Pulido
E
,
Castellano
DE
,
Garcia-Carbonero
R
,
Teule
A
,
Duran
I
,
Fuster
J
, et al.
PAZONET: Results of a phase II trial of pazopanib as a sequencing treatment in progressive metastatic neuroendocrine tumors (NETs) patients (pts), on behalf of the Spanish task force for NETs (GETNE)—NCT01280201
.
American Society of Clinical Oncology
;
2012
.
97.
Yao
JC
,
Phan
A
,
Hoff
PM
,
Chen
HX
,
Charnsangavej
C
,
Yeung
SC
, et al.
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b
.
J Clin Oncol
.
2008
Mar
;
26
(
8
):
1316
23
.
[PubMed]
0732-183X
98.
Chong
CR
,
Wirth
LJ
,
Nishino
M
,
Chen
AB
,
Sholl
LM
,
Kulke
MH
, et al.
Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors
.
Lung Cancer
.
2014
Nov
;
86
(
2
):
241
6
.
[PubMed]
0169-5002
99.
García-Yuste
M
,
Matilla
JM
,
Cueto
A
,
Paniagua
JM
,
Ramos
G
,
Cañizares
MA
, et al.;
Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung for the Spanish Society of Pneumonology and Thoracic Surgery (EMETNE-SEPAR)
.
Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung
.
Eur J Cardiothorac Surg
.
2007
Feb
;
31
(
2
):
192
7
.
[PubMed]
1010-7940
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.